solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Company profile
Ticker
SLDB
Exchange
Website
CEO
Ilan Ganot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Solid Biosciences, LLC
SEC CIK
Corporate docs
Subsidiaries
AavantiBio, Inc. • Solid Biosciences Securities Corporation ...
SLDB stock data
Latest filings (excl ownership)
S-3
Shelf registration
13 Mar 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
5 Feb 24
S-3
Shelf registration
30 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
15 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.87 mm | 50.87 mm | 50.87 mm | 50.87 mm | 50.87 mm | 50.87 mm |
Cash burn (monthly) | 14.18 mm | (no burn) | 7.70 mm | 9.71 mm | 5.97 mm | 8.99 mm |
Cash used (since last report) | 84.45 mm | n/a | 45.90 mm | 57.86 mm | 35.54 mm | 53.53 mm |
Cash remaining | -33.58 mm | n/a | 4.97 mm | -6.99 mm | 15.33 mm | -2.66 mm |
Runway (months of cash) | -2.4 | n/a | 0.6 | -0.7 | 2.6 | -0.3 |
Institutional ownership, Q2 2023
70.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 10 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 73.30 bn |
Total shares | 26.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RARE Ultragenyx Pharmaceutical | 7.83 mm | $26.84 mm |
Perceptive Advisors | 3.50 mm | $18.32 bn |
Ra Capital Management | 3.43 mm | $17.95 bn |
Bain Capital Life Sciences Investors | 3.13 mm | $16.40 bn |
BCLS SB Investco | 2.30 mm | $15.58 mm |
Camber Capital Management | 1.42 mm | $7.43 mm |
Finepoint Capital | 961.25 k | $5.04 bn |
Laurion Capital Management | 928.17 k | $4.86 bn |
Artal | 909.22 k | $4.76 mm |
Alyeska Investment | 646.60 k | $3.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 24 | Ganot Ilan | RSU Common Stock | Grant | Acquire A | Yes | No | 0 | 19,444 | 0.00 | 19,444 |
13 Feb 24 | Kevin Tan | RSU Common Stock | Grant | Acquire A | No | No | 0 | 42,500 | 0.00 | 42,500 |
13 Feb 24 | Kevin Tan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.85 | 85,000 | 667.25 k | 85,000 |
13 Feb 24 | David T Howton | RSU Common Stock | Grant | Acquire A | No | No | 0 | 58,750 | 0.00 | 58,750 |
13 Feb 24 | David T Howton | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.85 | 117,500 | 922.38 k | 117,500 |
13 Feb 24 | Jennifer Marlowe | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Jennifer Marlowe | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.85 | 90,000 | 706.50 k | 90,000 |
13 Feb 24 | Gabriel Brooks | RSU Common Stock | Grant | Acquire A | No | No | 0 | 43,750 | 0.00 | 43,750 |
13 Feb 24 | Gabriel Brooks | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.85 | 87,500 | 686.88 k | 87,500 |
News
Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $21
18 Mar 24
Citigroup Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $16
15 Mar 24
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
15 Mar 24
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
14 Mar 24
Piper Sandler Upgrades Solid Biosciences to Overweight, Raises Price Target to $20
14 Mar 24
Press releases
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
13 Mar 24
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
7 Mar 24
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
16 Jan 24
Solid Biosciences Announces $109 Million Private Placement
8 Jan 24